Chris Twelves - Concepedia

Author

Chris Twelves

St James's University Hospital

Also Known As

C Twelves, C. Twelves, Chris C. Twelves, Chris Twelves

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

St James's University Hospital University of Leeds Leeds Teaching Hospitals NHS Trust Institut Jules Bordet Vall d'Hebron Institute of Oncology

About

Chris Twelves is an author at St James's University Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	1.3K
2	Health Sciences	6	6	445
3	Public Health	2	2	259
4	Engineering	1	1	97
5	Nursing	1	1	162

Chris Twelves

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane Peter A. Kaufman, Ahmad Awada, Chris Twelves, Journal of Clinical Oncology	2015	442
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine Javier Cortés, Linda T. Vahdat, Joanne L. Blum, Journal of Clinical Oncology	2010	215
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies Chris Twelves, Javier Cortés, Linda T. Vahdat, Breast Cancer Research and Treatment	2014	205
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial Peter Barrett‐Lee, Lindsay Johnson, David Cameron, The Lancet Breast OncologyOncologyPhase IiiClinical TrialsAdjuvant Chemotherapy	2009	188
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials Thierry Gorlia, Roger Stupp, Alba A. Brandes, European Journal of Cancer Neuro-oncologyPrognostic EvaluationMedicineOutcome PredictionPrognosis	2012	185
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial Alasdair Munro, Shuo Feng, Leila Janani, The Lancet Infectious Diseases	2022	170
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials Hans‐Joachim Schmoll, Chris Twelves, Weijing Sun, The Lancet Oncology Gastrointestinal OncologyMedicineIndividual Patient DataAdjuvant CapecitabinePost-relapse Survival	2014	166
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer Fabio Efficace, Laura Biganzoli, Martine Piccart, European Journal of Cancer NursingQuality Of LifePrognostic FactorsMetastatic Breast CancerLife Assessment	2004	162
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Chris Twelves, Rob Glynne‐Jones, Jim Cassidy, PubMed Hepatic DysfunctionChemoprevention StrategyPathologyPharmacotherapyTumor Biology	1999	158
Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer Chris Twelves, Javier Cortés, Linda T. Vahdat, Clinical Breast Cancer Metastatic Breast CancerBreast OncologyPhase Iii TrialsMedicineLocally Recurrent	2010	106

Page 1